Book 01 / Healthspan & evidence
The Longevity Operating System
Mark A. Smith
A Practical, Evidence-Literate Guide to Healthspan, Measurement, and Self-Experimentation
Book 04 of the Longevity Evidence Series / GLP-1 & metabolic health
The Metabolic Frontier
GLP-1 Medicines, Emerging Peptides, Gray-Market Risks, and the Science of Better Body Composition
By Mark A. Smith
From appetite and cardiovascular outcomes to lean mass and long-term maintenance, a close reading of GLP-1 evidence. Emerging peptides, compounding, and gray-market products are examined with clear attention to safety and regulatory distinctions.
Download free PDFFree edition · 356 pages · 9.3 MB · No account needed
About this book
The Metabolic Frontier explains how hunger became treatable — from a century of research to the receptor biology behind today’s GLP-1 medicines — and teaches you to read a weight-loss trial without being sold.
It covers what semaglutide and tirzepatide actually prove, side effects and red flags, and why lean mass is not a synonym for muscle, with a practical muscle-preservation and nutrition focus. The final parts examine compounding, peptide stacks, and the gray market, with close attention to safety and regulatory distinctions.
What’s inside
How hunger became treatable
- The Week the Food Noise Stopped
- A Century Before the Blockbuster
- The Receptor Orchestra
- What Counts as a GLP-1 Drug?
What the medicines actually prove
- Reading a Weight-Loss Trial Without Being Sold
- Semaglutide: From Scale to Outcomes
- Tirzepatide and the Dual-Agonist Leap
- Pills, Pens, and the Adherence Problem
- The Conditions Behind the Weight
Losing weight without losing the person
- Side Effects, Warnings, and Red Flags
- Lean Mass Is Not a Synonym for Muscle
- The Muscle-Preservation Plan
- When Appetite Is Small, Nutrition Matters More
- Supplements, Body-Composition Drugs, and Peptide Stacks
The market outside the label
- Why Access Broke the Care Model
- Compounding Is Not Generic Manufacturing
- The Vial Adds a System
- Inside the Gray Market
- What a Lab Result Cannot Promise
More from the series
Book 02 / Rapamycin & muscle
mTOR, Metabolism, and Muscle
Mark A. Smith
Rapamycin, Exercise, and the Biology of Longevity Trade-offs
Book 03 / Brain health & prevention
Outrunning Alzheimer’s
Mark A. Smith
What a Global Longevity Community Tested—and What the Evidence Now Says About Protecting Your Brain